Talaris Therapeutics On Sept 22, Co Got Purported Notice Of Material Breach From Immunofree Alleging That Co Breached Provision Of Apa June 28; On Oct 6 Co And Immunofree Executed Binding Settlement Agreement Pursuant To Which The Co To Pay Immunofree $4M
Portfolio Pulse from Benzinga Newsdesk
Talaris Therapeutics has received a notice of material breach from Immunofree, alleging that the company breached a provision of APA June 28. On October 6, Talaris and Immunofree executed a binding settlement agreement, with Talaris agreeing to pay Immunofree $4M.
October 10, 2023 | 8:50 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Talaris Therapeutics has settled a legal dispute with Immunofree for $4M, which could impact the company's financials in the short term.
The settlement of $4M is a significant expense for Talaris Therapeutics and could negatively impact the company's financial performance in the short term. This could potentially lead to a decrease in the company's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100